Bavarian Nordic COVID booster shot reveals efficacy 6-months after vaccination in trial

Bavarian Nordic (OTCPK:BVNRY) (OTCPK:BVNKF) (BAVN) mentioned it its COVID-19 booster vaccine ABNCoV2 confirmed sturdy antibody response six months after vaccination in a part 2 trial.

The corporate famous that beforehand reported outcomes from the examine confirmed, 100ug ABNCoV2 in 103 seropositive individuals was in a position to present a powerful boosting impact, rising the prevailing ranges of novel coronavirus neutralizing antibodies in opposition to the Wuhan variant and variants of concern (Alpha, Beta, Delta and Omicron) to ranges reported to be extremely efficacious (>90%) in opposition to SARS-CoV-2.

Bavarian added {that a} group of 41 individuals had been adopted for six months after vaccination. On this group, two individuals with confirmed COVID-19 had been excluded from the immune evaluation.

After six months of vaccination, neutralization titers had been six occasions greater than pre-boost titers in opposition to Wuhan and practically 10 occasions greater than the pre-boost titers for Omicron BA.1, the Danish firm famous.

Bavarian added that this represented lower than a 50% decline in peak neutralizing titers after six months and in comparison with the information revealed for mRNA vaccines, the antibody decay appeared much less sharp, suggesting a doubtlessly longer period of safety throughout variants.

“These newest information additional help the idea that ABNCoV2 might be a common booster vaccine inducing sturdy and sturdy immune responses in opposition to all main variants of concern, together with Omicron, with out the necessity to modify the vaccine. We sit up for producing additional information within the ongoing Part 3 trial that may shortly open websites in Denmark,” mentioned Bavarian President and CEO Paul Chaplin.

The corporate famous that in September it began a part 3 trial to guage the non-inferiority of ABNCoV2 in comparison with Pfizer (PFE) and BioNTech’s (BNTX) Comirnaty. The examine expects to enroll ~4,000 individuals who both beforehand accomplished major vaccination or have already acquired one booster dose of a COVID vaccine.

Enrollment within the first group, which would come with ~3K individuals, within the U.S. has already begun.